現在の所属組織 【 表示 ／ 非表示 】

現在の所属組織 【 表示 ／ 非表示 】

留学歴 【 表示 ／ 非表示 】

留学歴 【 表示 ／ 非表示 】

取得学位 【 表示 ／ 非表示 】

取得学位 【 表示 ／ 非表示 】

職歴 【 表示 ／ 非表示 】

職歴 【 表示 ／ 非表示 】

研究キーワード 【 表示 ／ 非表示 】

研究キーワード 【 表示 ／ 非表示 】

研究分野 【 表示 ／ 非表示 】

研究分野 【 表示 ／ 非表示 】

主たる研究テーマ 【 表示 ／ 非表示 】

主たる研究テーマ 【 表示 ／ 非表示 】

• 維持血液透析患者におけるCD34と心血管合併症の危険因子

• 維持血液透析患者の生命予後におけるアルドステロンの意義

• ヒト腎臓におけるNAD(P)H Oxidase発現とその病態における意義

論文 【 表示 ／ 非表示 】

論文 【 表示 ／ 非表示 】

• Reply to a letter to the editor regarding "Heterogeneous afferent arteriolopathy: a key concept for understanding blood pressure-dependent renal damage".

  Kohagura K

  Hypertension research : official journal of the Japanese Society of Hypertension     2025年09月 [ 査読有り ]

  掲載種別: 研究論文（学術雑誌）

  • この論文にアクセスする

    DOI
  • 関連情報を調べる
    PubMed

• Sustained eGFR improvement after dapagliflozin in a patient with antiretroviral therapy-related chronic kidney disease.

  Arae H, Hoshino S, Moromi N, Tokumine K, Kohagura K

  CEN case reports ( Cen Case Reports )    2025年08月 [ 査読有り ]

  掲載種別: 研究論文（学術雑誌）

  • この論文にアクセスする

    DOI
  • 関連情報を調べる
    PubMed

• Role of time in target range in blood pressure management for preventing renal decline in type 2 diabetes.

  Kohagura K

  Hypertension research : official journal of the Japanese Society of Hypertension ( Hypertension Research )  48 ( 7 ) 2119 - 2121   2025年07月 [ 査読有り ]

  掲載種別: 研究論文（学術雑誌）

  • この論文にアクセスする

    DOI
  • 関連情報を調べる
    PubMed

• Heterogeneous afferent arteriolopathy: a key concept for understanding blood pressure-dependent renal damage

  Kohagura, K; Zamami, R; Oshiro, N; Shinzato, Y; Uesugi, N

  HYPERTENSION RESEARCH ( Springer Nature )  47 ( 12 ) 3383 - 3396   2024年12月

  掲載種別: 研究論文（学術雑誌）

  　概要を見る

  Hypertension, aging, and other factors are associated with arteriosclerosis and arteriolosclerosis, primary morphologicalfeatures of nephrosclerosis. Although such pathological changes are not invariably linked with renal decline but areprevalent across chronic kidney disease (CKD), understanding kidney damage progression is more pragmatic than preciselydiagnosing nephrosclerosis itself. Hyalinosis and medial thickening of the afferent arteriole, along with intimal thickening ofsmall arteries, can disrupt the autoregulatory system, jeopardizing glomerular perfusion pressure given systemic bloodpressure (BP) fluctuations. Consequently, such vascular lesions cause glomerular damage by inducing glomerularhypertension and ischemia at the single nephron level. Thus, the interaction between systemic BP and afferent arteriolopathymarkedly influences BP-dependent renal damage progression in nephrosclerosis. Both dilated and narrowed types of afferentarteriolopathy coexist throughout the kidney, with varying proportions among patients. Therefore, optimizingantihypertensive therapy to target either glomerular hypertension or ischemia is imperative. In recent years, clinical trialshave indicated that combining renin–angiotensin system inhibitors (RASis) and sodium–glucose transporter 2 inhibitors(SGLT2is) is superior to using RASis alone in slowing renal function decline, despite comparable reductions in albuminuria.The superior efficacy of SGLT2is may arise from their beneficial effects on both glomerular hypertension and renalischemia. A comprehensive understanding of the interaction between systemic BP and heterogeneous afferent arteriolopathyis pivotal for optimizing therapy and mitigating renal decline in patients with CKD of any etiology. Therefore, in thiscomprehensive review, we explore the role of afferent arteriolopathy in BP-dependent renal damage.

  • この論文にアクセスする

    DOI
  • 関連情報を調べる
    PubMed CiNii Research

• Efficacy and safety of early administration of remdesivir in hemodialysis patients with COVID-19: A case report and literature review

  Oshiro Nanako, Kinjo Takeshi, Aharen Daigo, Kudo Yuki, Katsuren Eisuke, Omine Kumiko, Nakamura Takuto, Zamami Ryo, Ishida Akio, Miyagi Kazuya, Nakamatsu Masashi, Yamamoto Kazuko, Kusunose Kenya, Fujita Jiro, Ohya Yusuke, Kohagura Kentaro

  Medicine ( Wolters Kluwer Health, Inc. )  103 ( 48 ) 1 - 5   2024年11月 [ 査読有り ]

  掲載種別: 研究論文（学術雑誌）

  　概要を見る

  Rationale: Although the mortality of severe coronavirus disease 2019 (COVID-19) has decreased after the emergence of the Omicron variant, it remains high in patients on hemodialysis (HD). Remdesivir (RDV) is considered as the first line drug for hospitalized COVID-19 patients, however the evidence regarding the usage in HD patients is lacking because clinical trials of RDV have excluded HD patients for safety reasons. Thus, accumulation of knowledge on the regimen, efficacy, and tolerability of RDV in HD patients is important. Patient concerns: A nosocomial COVID-19 cluster was occurred from August 31 to October 12 in 2021 when the Delta variant was predominant. During the cluster, 11 health-care workers and 20 inpatients including 7 HD patients were infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Diagnoses: The diagnosis of COVID-19 was confirmed by the real-time polymerase chain reaction (PCR) for SARS-CoV-2. Interventions: RDV was initiated within 16 hours after the onset of fever (≥ 37.4°C) or positive PCR result in all HD patients, and continued at 100 mg/day intravenously once daily for either consecutive 5 or 10 days. Outcomes: All patients fully recovered within 2 weeks and did not develop severe COVID-19. Two patients experienced mild liver dysfunction, but it was temporary and remitted spontaneously even continuing RDV treatment. Discontinuation of RDV therapy due to adverse events was not required in any patients. Lessons: Present cases indicated early intervention with RDV may contribute the favorable outcome and daily administration of RDV for up to 10 days was well tolerated even in HD patients. Literature review showed no previous article reported the efficacy and safety of such earlier and longer administration of remdesivir as in the present cases, therefore this report is informative for clinicians to consider the usage of RDV in HD patients.

  • 関連情報を調べる
    CiNii Research

全件表示 >>

科研費獲得情報 【 表示 ／ 非表示 】

科研費獲得情報 【 表示 ／ 非表示 】

• ヒト腎臓におけるNAD(P)H Oxidase発現とその病態における意義

  ■■■

  課題番号: 00000000

  研究期間: 1900年01月  -  1900年01月 

  直接経費: 0（円）  間接経費: 0（円）  金額合計: 0（円）